![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 23 of 23. This is the beginning of the thread.
Posted by Tomatheus on September 10, 2015, at 17:12:30
Press release: U.S. FDA accepts first digital medicine New Drug Application for Otsuka and Proteus Digital Health
* The first Digital Medicine, a drug/device product, combines Otsukas ABILIFY® (aripiprazole) for serious mental illness, embedded with the Proteus® ingestible sensor in a single tablet to digitally record ingestion and, with patient consent, share information with their healthcare professionals and caregivers
* Otsuka and Proteus are pursuing a regulatory filing for a drug-device combination across multiple divisions of the FDA to support the unique system
* First opportunity to demonstrate the potential of Digital Medicines to provide an objective measure of medication adherence and physiologic response
TOKYO & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announced that the United States Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) for the combination product of Abilify® (aripiprazole) embedded with a Proteus® ingestible sensor in a single tablet is sufficiently complete to allow for a substantive review and is considered filed as of Sept. 8, 2015.
This is the first time an FDA-approved medication (Abilify) has been combined and submitted for approval with a sensor within the medication tablet (the Proteus ingestible sensor) to measure actual medication-taking patterns and physiologic response. This objective information is communicated to the patient - and with the consent of the patient - to the patient's physician and/or caregiver. Digital Medicines may enable improved patient medication adherence and better informed physician decision-making to tailor treatment to the patient's needs.
An estimated average of 50% of patients with chronic diseases in developed countries do not take medicines as prescribed, possibly limiting the effectiveness of those medicines. In the U.S., this may result in an estimated $100-300 billion in avoidable healthcare costs due to direct costs such as unnecessary escalation of treatment as well as indirect costs.1,2 For example, patients suffering from chronic mental disorders such as schizophrenia are often required to take medication for long periods, and it is not unusual for these patients to discontinue taking their medication, or not take their medication as prescribed, which can lead to disease relapse and recurrence.3,4
The Abilify tablet contains an ingestible sensor that communicates with a wearable sensor patch and a medical software application for measuring adherence in the treatment of adults with schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, and as adjunctive therapy for the treatment of major depressive disorder in adults.
"Today, patients suffering from severe mental illnesses struggle with adhering to or communicating with their healthcare teams about their medication regimen, which can greatly impact outcomes and disease progression," said William H. Carson, M.D., president and CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. "We believe this new Digital Medicine could revolutionize the way adherence is measured and fulfill a serious unmet medical need in this population. We look forward to continuing working with the FDA throughout the NDA review."
If approved by the FDA, healthcare professionals will have the ability to prescribe Abilify tablets with the Proteus ingestible sensor embedded in the tablet. This drug-device product can provide the patient with a treatment option to help manage symptoms while allowing the caregiver and healthcare professional to measure medication adherence and other patient metrics. This unique system is filed as an NDA, where the FDA Center for Devices and Radiological Health (CDRH)-cleared ingestible sensor from Proteus will be embedded at the point of manufacture with the FDA Center for Drug Evaluation and Research (CDER)-approved Abilify as a combination drug-device, communicating with the Proteus patch and associated medical software.
"Digital Medicines have the potential to move healthcare beyond the proven efficacy of a medicine to understand the real-world effectiveness of a therapy for each individual," said Andrew Thompson, president and CEO of Proteus Digital Health. "This means that medicines could be tailored to each of us to reflect our unique medication-taking patterns, lifestyle and daily health choices."
When Abilify with the embedded ingestible sensor is taken, the ingestible sensor sends a signal to the wearable Proteus patch after it reaches the stomach. The patch records and time-stamps the information from the ingestible sensor in addition to collecting other patient metrics, including rest, body angle and activity patterns. This information is recorded and relayed to patients on a mobile phone or other Bluetooth-enabled device, and only with their consent, to their physician and/or their caregivers. Patients view the information using a secure and local software application on their mobile phone or device. Physicians and caregivers view the data using secure web portals.
==
INDICATIONS and IMPORTANT SAFETY INFORMATION for ABILIFY® (aripiprazole)
INDICATIONS
ABILIFY is indicated for:
Use as an adjunctive therapy to antidepressants in adults with Major Depressive Disorder who have had an inadequate response to antidepressant therapy
Acute treatment of manic or mixed episodes associated with Bipolar I Disorder as monotherapy and as an adjunct to lithium or valproate in adult
Treatment of Schizophrenia in adults
IMPORTANT SAFETY INFORMATION
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death compared to placebo (4.5% vs 2.6%, respectively). Although the causes of death were varied, most of the deaths appeared to be cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. ABILIFY is not approved for the treatment of patients with dementia-related psychosis.
Suicidal Thoughts and Behaviors
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of adjunctive ABILIFY or another antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increased risk of suicidality in adults beyond age 24. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. ABILIFY is not approved for use in pediatric patients with depression.
See Full Prescribing Information for complete Boxed WARNING
Contraindication Known hypersensitivity reaction to ABILIFY. Reactions have ranged from pruritus/urticaria to anaphylaxis.
Cerebrovascular Adverse Events, Including Stroke Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, have been reported in clinical trials of elderly patients with dementia-related psychosis treated with ABILIFY
Neuroleptic Malignant Syndrome (NMS) As with all antipsychotic medications, a rare and potentially fatal condition known as NMS has been reported with ABILIFY. NMS can cause hyperpyrexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental status. Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems
Tardive Dyskinesia (TD) The risk of developing TD and the potential for it to become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Prescribing should be consistent with the need to minimize TD. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn
Metabolic Changes Atypical antipsychotic drugs have been associated with metabolic changes that include:
Hyperglycemia/Diabetes Mellitus Hyperglycemia, in some cases extreme and associated with ketoacidosis, coma, or death, has been reported in patients treated with atypical antipsychotics including ABILIFY. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug
Dyslipidemia- Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics. There were no significant differences between Abilify- and placebo-treated patients in the proportion with changes from normal to clinically significant levels for fasting/nonfasting total cholesterol, fasting triglycerides, fasting LDLs, and fasting/nonfasting HDLs
Weight Gain- Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended. When treating pediatric patients, weight gain should be monitored and assessed against that expected for normal growth
Orthostatic Hypotension ABILIFY may be associated with orthostatic hypotension and should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions which would predispose them to hypotension.
Leukopenia, Neutropenia, and Agranulocytosis Leukopenia, neutropenia, and agranulocytosis have been reported with antipsychotics, including ABILIFY. Patients with history of a clinically significant low white blood cell (WBC) count or drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of ABILIFY should be considered at the first sign of a clinically significant decline in WBC count in the absence of other causative factors.
Seizures/Convulsions As with other antipsychotic drugs, ABILIFY should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold (e.g., Alzheimers dementia).
Potential for Cognitive and Motor Impairment Like other antipsychotics, ABILIFY may have the potential to impair judgment, thinking, or motor skills. Patients should not drive or operate hazardous machinery until they are certain ABILIFY does not affect them adversely.
Body Temperature Regulation Disruption of the bodys ability to reduce core body temperature has been attributed to antipsychotics. Appropriate care is advised for patients who may exercise strenuously, be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or be subject to dehydration.
Suicide The possibility of a suicide attempt is inherent in psychotic illnesses, Bipolar Disorder, and Major Depressive Disorder, and close supervision of high-risk patients should accompany drug therapy. Prescriptions should be written for the smallest quantity consistent with good patient management in order to reduce the risk of overdose.
Dysphagia Esophageal dysmotility and aspiration have been associated with antipsychotic drug use, including ABILIFY; use caution in patients at risk for aspiration pneumonia. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimers dementia.
Physicians should advise patients to avoid alcohol while taking ABILIFY.
Strong CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., fluoxetine) inhibitors will increase ABILIFY drug concentrations; reduce ABILIFY dose by one-half when used concomitantly, except when used as adjunctive treatment with antidepressants in adults with Major Depressive Disorder. If a strong CYP3A4 inhibitor and strong CYP2D6 inhibitor are co-administered or a known CYP2D6 poor metabolizer is receiving a concomitant strong CYP3A4 inhibitor, the ABILIFY dose should be reduced to one-quarter (25%) of the usual dose.
CYP3A4 inducers (e.g., carbamazepine) will decrease ABILIFY drug concentrations; double ABILIFY dose when used concomitantly.
Commonly observed adverse reactions: (≥5% incidence and at least twice the rate of placebo for ABILIFY vs placebo, respectively):
Adult patients with Major Depressive Disorder (adjunctive treatment to antidepressant therapy): akathisia (25% vs 4%), restlessness (12% vs 2%), insomnia (8% vs 2%), constipation (5% vs 2%), fatigue (8% vs 4%), and blurred vision (6% vs 1%)
Adult patients (monotherapy) with Bipolar Mania: akathisia (13% vs 4%), sedation (8% vs 3%), tremor (6% vs 3%), restlessness (6% vs 3%), and extrapyramidal disorder (5% vs 2%)
Adult patients with Schizophrenia: akathisia (8% vs 4%)
Dystonia is a class effect of antipsychotic drugs. Symptoms of dystonia may occur in susceptible individuals during the first days of treatment and at low doses.
Pregnancy: Non-Teratogenic Effects Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. These complications have varied in severity; from being self-limited to requiring intensive care and prolonged hospitalization. ABILIFY should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers - ABILIFY is excreted in human breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Please see accompanying FULL PRESCRIBING INFORMATION, including Boxed WARNING, for ABILIFY.
About ABILIFY® (aripiprazole)
Discovered by Otsuka Pharmaceutical Co., Ltd., ABILIFY was the first available dopamine partial agonist and is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, the maintenance treatment of bipolar I disorder, treatment of schizophrenia in adults, and as an adjunctive treatment to an antidepressant in adults with major depressive disorder who have an inadequate response to antidepressant therapy. ABILIFY Tablets are available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg strengths. Otsuka welcomes you to visit its U.S. website for more information about ABILIFY, and its global website for more information about the company.
About the Proteus® Ingestible Sensor and Wearable Patch
The Proteus ingestible sensor and wearable patch have been cleared by the Food and Drug Administration (FDA) for use in the United States, and CE marked per the Medical Device Directive for use in the European Union. More information is available at www.proteus.com.
==
REFERENCES
1 Sabaté E, editor. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003.
2 Iuga AO, McGuire MJ. Adherence and health care costs. Risk Management and Healthcare Policy. 2014;7:35-44.
3 Lehman, AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004 Feb;161(2 Suppl): 1-56.
4 Masand, PS1, Roca M, Turner MS, Kane JM. Prim care companion. J Clin Psychiatry. 2009;11(4):147-54.
==
Contacts
Otsuka Media:
In U.S.
Kimberly Whitefield, +1 609-535-9259
kimberly.whitefield@otsuka-us.com
Corporate Communications
Otsuka Pharmaceutical
Development & Commercialization, Inc.
or
Outside U.S.
Jeffrey Gilbert, +81 80 8728 6039 (Japan)
Gilbert.jeffrey@Otsuka.jp
Public Relations
Otsuka Pharmaceutical, Co., Ltd.
or
Proteus Digital Health Media:
Robin Suchan, +1 650-637-6221
rsuchan@proteus.com
Corporate Communications
Proteus Digital Health==
====================
Tomatheus' comments on this press release:
What Otsuka and Proteus seem to be aiming to do with this "digital medicine" bothers me, to say the least. One of the supposed goals of creating this sensor-embedded version of Abilify is to boost patient compliance, but I think that this product has the potential to have the reverse effect because I suspect that certain patients might be less willing to take Abilify to begin with if they know that it has a sensor in it literally monitoring their every move. Additionally, it's my opinion that the last thing that people prone to delusional thinking need is to have their pills embedded with sensors that could relay various bits of information to their doctors and caregivers. Too many individuals with psychotic disorders and mood disorders with psychotic features already hold delusional beliefs about being implanted with microchips, and I think that giving a sensor-embedded version of Abilify to such patients could easily intensify -- and perhaps, in some ways, legitimize -- such delusions. Finally, I think it's a shame that with all of the shortcomings and drawbacks that the pharmaceutical treatments of psychiatric disorders possess that the pharmaceutical industry can't instead focus its energy on making better medications. If this is the best "improvement" that the pharmaceutical industry can come up with, then that, in my opinion, is pretty sad.
Tomatheus
Posted by SLS on September 10, 2015, at 21:41:05
In reply to FDA accepts NDA for sensor-embedded Abilify, posted by Tomatheus on September 10, 2015, at 17:12:30
> Tomatheus' comments on this press release:
>
> What Otsuka and Proteus seem to be aiming to do with this "digital medicine" bothers me, to say the least. One of the supposed goals of creating this sensor-embedded version of Abilify is to boost patient compliance, but I think that this product has the potential to have the reverse effect because I suspect that certain patients might be less willing to take Abilify to begin with if they know that it has a sensor in it literally monitoring their every move. Additionally, it's my opinion that the last thing that people prone to delusional thinking need is to have their pills embedded with sensors that could relay various bits of information to their doctors and caregivers. Too many individuals with psychotic disorders and mood disorders with psychotic features already hold delusional beliefs about being implanted with microchips, and I think that giving a sensor-embedded version of Abilify to such patients could easily intensify -- and perhaps, in some ways, legitimize -- such delusions. Finally, I think it's a shame that with all of the shortcomings and drawbacks that the pharmaceutical treatments of psychiatric disorders possess that the pharmaceutical industry can't instead focus its energy on making better medications. If this is the best "improvement" that the pharmaceutical industry can come up with, then that, in my opinion, is pretty sad.
>
> Tomatheus
You make some excellent points. I hope they have already been considered by the manufacturers. If compliance is an issue, it would have been nice to see a monthly injectable be developed.
- Scott
Posted by Tomatheus on September 10, 2015, at 22:03:04
In reply to Re: FDA accepts NDA for sensor-embedded Abilify » Tomatheus, posted by SLS on September 10, 2015, at 21:41:05
> You make some excellent points. I hope they have already been considered by the manufacturers. If compliance is an issue, it would have been nice to see a monthly injectable be developed.
>
>
> - ScottIt's my understanding that Abilify Maintena, a long-acting injectable version of Abilify, has been developed, but it seems that the makers want to take things a step further. I suppose we'll see whether the FDA will approve this. I can understand the arguments that a sensor-embedded Abilify might be beneficial to the extent that it might help increase compliance to the medication (although, as I pointed out in my previous post, it might also have the reverse effect) and also to the extent that it might give doctors some idea how well the medication is working, but I personally find this whole idea to be too problematic.
Tomatheus
Posted by FloydAS on September 11, 2015, at 8:01:37
In reply to FDA accepts NDA for sensor-embedded Abilify, posted by Tomatheus on September 10, 2015, at 17:12:30
This seems to be a slippery slope to me. Who would consent to something like this unless they're really having major issues? The only way I see this being successful for drug manufacturers is if this digital sensor became standard for every drug and consent became mandatory by default.
It is interesting that Abilify was chosen as a guinea pig as opposed to pain medications that are repeat offenders for being abused. I can see that as a potential purpose for this concept.
The only part of the population that I foresee really benefiting from something like this would be the elderly and many of those that require treatment are already utilizing assistance with their medication anyway. I just don't see this as viable unless this is dictated by Washington which God forbid it ever is. I see their facts and figures in the article but I really would be shocked if enough of the population consents to something this intrusive to make it profitable to the drug manufacturers in the long run.
And heck, my prescription drug plan, CVS Caremark, just eliminated Abilify from coverage in their formulary for 2016 as it is, which is an interesting aside to this particular article given the timing.
Posted by herpills on September 11, 2015, at 9:11:32
In reply to FDA accepts NDA for sensor-embedded Abilify, posted by Tomatheus on September 10, 2015, at 17:12:30
Great points, I agree with everything you are saying. I also don't really see how this would increase compliance. It could certainly help to identify IF someone is taken their medication, but how it's going to actually MAKE people take it doesn't make sense to me. I also agree, all the money spent to develop this, could have gone towards making new medications available which are more effective and have less side effects.
Posted by Christ_empowered on September 11, 2015, at 11:01:03
In reply to Re: FDA accepts NDA for sensor-embedded Abilify » Tomatheus, posted by herpills on September 11, 2015, at 9:11:32
hmmmm..."patent extender." Probably cheaper to make the 1984 version of Abillify than to make a new medication that actually outdoes Abilify.
I don't like this at all. I take (now generic) Abilify. Its OK, as antipsychotics go. Probably better than the competition, for me at least. But...Abilify+surveillance technology? No thanks, *ssh*l*.
Posted by Jeroen on September 11, 2015, at 15:03:03
In reply to Re: FDA accepts NDA for sensor-embedded Abilify » SLS, posted by Tomatheus on September 10, 2015, at 22:03:04
IS A PRO BIOTIC WITH L-GLUTAMINE 1500 MG WISE???
i have psychosis with schizophrenia... the pro biotic name is Nutrimonium
i'm scared to try
Posted by Tomatheus on September 11, 2015, at 15:42:27
In reply to Re: FDA accepts NDA for sensor-embedded Abilify » Tomatheus, posted by FloydAS on September 11, 2015, at 8:01:37
Thank you all for your comments. It's good to know that I'm not the only person who thinks that a sensor-embedded version of Abilify would be a bad idea.
FloydAS - You made some really good points in your post, and I especially agree with you on the point that a lot of patients would likely object to taking this version of Abilify, which would affect its profitability. Doctors who would otherwise prescribe Abilify to patients who are under a court order to take medication might see a sensor-embedded version of the medication as an option that might provide them with some feedback on how well patients are doing on the medication, but the number of patients who are court-ordered specifically to take a version of aripiprazole is probably quite low. So, perhaps there are some patient populations for whom this sensor-embedded Abilify might be seen as an advance over regular aripiprazole tablets, but I think that such patients would likely make up a very small percentage of those who would take aripiprazole.
Herpills - Thank you for your feedback. It definitely sounds like we're in agreement.
Christ_empowered - I definitely have the same displeasure -- or at least similar displeasure -- toward this idea that you do. And I agree with you that this could more or less amount to a "patent extender" of Abilify. Then again, I thought that Rexulti was supposed to be Abilify's patent extender. Maybe Rexulti wasn't good enough for the medication's makers? Who knows?
Tomatheus
Posted by Tomatheus on September 11, 2015, at 15:48:23
In reply to IS A PRO BIOTIC WITH L-GLUTAMINE 1500 MG WISE???, posted by Jeroen on September 11, 2015, at 15:03:03
Jeroen,
I'm not sure how wise it would be overall to take the Nutrimonium supplement that you're asking about. I can say that I experience some psychotic or psychotic-like symptoms myself and that I had a bad experience with l-glutamine when I tried it. Basically, certain visual perceptual problems that I experience intensified.
Having said what I've said, it might be possible that you'd do better on l-glutamine than I did or that taking the l-glutamine/probiotic combo might have a different effect than l-glutamine alone. As you probably know, individual responses to supplements and medications can vary to a great extent from one individual to the next. But I can say that for me, l-glutamine was no good.
Tomatheus
Posted by Jeroen on September 11, 2015, at 15:57:11
In reply to Re: IS A PRO BIOTIC WITH L-GLUTAMINE 1500 MG WISE??? » Jeroen, posted by Tomatheus on September 11, 2015, at 15:48:23
thanks for your reply, i needed that, i read good stuff and bad stuff about it, people react different to it... i dunno what to do
tried Glycine with seroquel XR and got 4 hours straight tachardia, amino acid years ago
100 mg XR didnt cause it , but 150 mg XR caused a severe reaction, please tell me what to do i have IBS for a year now i need a treatment for that or is it just lost : (
Posted by Tomatheus on September 11, 2015, at 16:34:42
In reply to To Tomatheus » Tomatheus, posted by Jeroen on September 11, 2015, at 15:57:11
Jeroen,
I must confess that I have next to no knowledge when it comes to the treatment of IBS. There might be others on this site with some medical knowledge who might be able to offer some suggestions, but I know so little about the treatment of IBS that it wouldn't be my place to offer suggestions.
As far as the treatment of your psychosis is concerned, are you currently taking any medications? And are you looking to boost any medication response that you might be experiencing with dietary supplements? I personally have not found a supplement that helps in the long run with the perceptual or hallucination-like problems that I experience and have only noticed clear reductions in these symptoms from certain medications. Glycine, sarcosine, and d-serine come to mind as supplements that could potentially help with psychotic symptoms, but I see that you didn't tolerate glycine well, so I don't know if it would be advisable to suggest the other supplements as options. What types of symptoms are you needing the most relief from?
Tomatheus
Posted by Jeroen on September 11, 2015, at 17:02:14
In reply to psychosis and IBS treatments » Jeroen, posted by Tomatheus on September 11, 2015, at 16:34:42
pos and neg symptoms with casual seizures by computer lights
Posted by Tomatheus on September 11, 2015, at 17:15:02
In reply to Re: psychosis and IBS treatments » Tomatheus, posted by Jeroen on September 11, 2015, at 17:02:14
Hmmm, Jeroen. It definitely sounds like you should be working with a doctor and that some sort of medication should be part of your treatment plan if it isn't already. Something that you might want to consider asking your doctor about is whether being evaluated for anti-NMDA-receptor encephalitis would be a good idea. Here in the U.S., a reporter from the New York Post wrote a book ("Brain on Fire") about her experiences with the illness and being treated for it, and the author's symptoms included psychosis and seizures. That, of course, doesn't necessarily mean that you have anti-NMDA-receptor encephalitis, but discussing it with your doctor is something that you might find to be worthwhile.
Tomatheus
Posted by linkadge on September 11, 2015, at 19:13:28
In reply to Re: psychosis and IBS treatments » Jeroen, posted by Tomatheus on September 11, 2015, at 17:15:02
Putting a tracer in medication is a terrible idea. I can imagine a paranoid schizophrenic who thinks that he is being monitored by an EM emitting tracer. Except, in this case, he actually is. I would have to wrap myself in tinfoil to avoid being monitored.
Also, I am not confident in the safety of a device emitting a radio wave literally travelling through your body, next to vital organs. If a cell phone can cause cancer, then what about an ingestible cell phone?
Doctors need to spend more time developing medications worth being compliant with, rather than more cunning ways of monitoring compliance of crappy meds.
Linkadge
Posted by Tomatheus on September 11, 2015, at 20:51:35
In reply to Re: terrible idea, posted by linkadge on September 11, 2015, at 19:13:28
Linkadge,
Thank you for your comments. You made some very good points, and I think I agree with every word of what you wrote. It definitely seems like this idea of embedding medications with sensors isn't too popular among those of us who use this medication board. I don't know if we're necessarily representative of the larger population of psychiatric patients who take medications (in fact, we're probably not), but I think that I can predict with some degree of certainty how this idea is going to be received by the population of psychiatric patients at large.
Tomatheus
Posted by Lamdage22 on September 12, 2015, at 7:55:07
In reply to To Tomatheus » Tomatheus, posted by Jeroen on September 11, 2015, at 15:57:11
Im with you Tomatheus.
It is a bitch move.
Posted by Lamdage22 on September 12, 2015, at 8:11:25
In reply to Re: terrible idea, posted by linkadge on September 11, 2015, at 19:13:28
> Doctors need to spend more time developing medications worth being compliant with, rather than more cunning ways of monitoring compliance of crappy meds.
>
> Linkadgeagree 100%
Posted by Tomatheus on September 12, 2015, at 13:40:30
In reply to Re: To Tomatheus, posted by Lamdage22 on September 12, 2015, at 7:55:07
Lamdage,
Thank you for your comments to this thread. I wonder if anyone on this board actually likes the idea of there being a sensor-embedded version of Abilify. Of course, neither of us seem to like this idea.
Tomatheus
Posted by Jeroen on September 13, 2015, at 6:28:22
In reply to To Lamdage22 » Lamdage22, posted by Tomatheus on September 12, 2015, at 13:40:30
took my first dose of nutrimonium do you know how long it takes to kick in
Posted by Tomatheus on September 13, 2015, at 16:36:42
In reply to Re: To Tomateus, posted by Jeroen on September 13, 2015, at 6:28:22
> took my first dose of nutrimonium do you know how long it takes to kick in
Jeroen,
I'm probably not the best person to ask about this, as it's been several years since I took l-glutamine, and I have no experience with probiotics. I will say that when I experienced visual perceptual problems on l-glutamine, I don't recall it taking more than two to three days for those effects to emerge. I discontinued the l-glutamine at that point, so I can't comment based on my experience on what a full trial with l-glutamine feels like.
I'm sorry that I couldn't be of more help.
Tomatheus
Posted by linkadge on September 15, 2015, at 19:03:43
In reply to Re: To Tomatheus, posted by Lamdage22 on September 12, 2015, at 7:55:07
I can't imagine where I'd be if I was compliant with the medications prescribed to me.
At one point, I was on lithium, Depakote, zyprexa, citalopram and (something else). Now, I'm on virtually nothing, and surprisingly doing better than before.
I take mini doses of meds, only when needed and then try to get off them ASAP.
I feel that I have gotten better by not being compliant.
Now, I know the scientific / medical community likes compliance. That way the variables are controlled and they can study us - sending us away for 8 weeks of this med and then another 8 weeks of that one.
I don't like that "experiment" process. That's 8 weeks of my life gone.
Linkadge
Posted by Tomatheus on September 21, 2015, at 18:15:31
In reply to FDA accepts NDA for sensor-embedded Abilify, posted by Tomatheus on September 10, 2015, at 17:12:30
An interesting article on this topic that I found on WIRED magazine's Web site:
"Why pharma wants to put sensors in this blockbuster drug"
http://www.wired.com/2015/09/pharma-wants-put-sensors-blockbuster-drug/
Tomatheus
Posted by Lamdage22 on September 23, 2015, at 7:11:52
In reply to Article from WIRED magazine's Web site, posted by Tomatheus on September 21, 2015, at 18:15:31
Forced drugging is what they are after instead of developing pills people actually WANT to take because they are so helpful.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.